The Sugar Beat

• The Burden of Undiagnosed Diabetes Dr Jain reviews the International Diabetes Federation Atlas, predicting an 'alarming' number of people living with undiagnosed diabetes — particularly youth.
  Medscape Diabetes & Endocrinology, April 12, 2022
• Will Wegovy Be of Little Use for Weight Loss? The weight loss drug heralded as a 'game changer' may be of little use unless we take care of a few hurdles first, says Dr Akshay Jain.
  Medscape Diabetes & Endocrinology, August 12, 2021
  6
• Top Studies, Highlights From ADA 2021   Drs Akshay Jain and Harpreet Bajaj give us their takes on the clinically relevant highlights from ADA 2021.
  Medscape Diabetes & Endocrinology, July 09, 2021
• Disparities in SGLT2i Use: Patient Barriers or Physician Bias? A recent study suggests that although the use of SGLT2 inhibitors has increased overall, certain groups are not being prescribed these medications. Dr Akshay Jain looks into possible reasons why.
  Medscape Diabetes & Endocrinology, May 12, 2021
  9
• EASD 2020 GLP-1 Receptor Agonists at EASD 2020: Poster Pearls Dr Akshay Jain shares his top poster picks on GLP-1 receptor agonists from this year's EASD virtual meeting.
  Medscape Diabetes & Endocrinology, December 11, 2020
• EASD 2020 New Diabetes Guidelines: 'Treat to Mitigate' Dr Akshay Jain reviews the new position statement from Primary Care Diabetes Europe on the management of type 2 diabetes.
  Medscape Diabetes & Endocrinology, October 29, 2020
  2
• EASD 2020 Once-Weekly 'Centennial Insulin': Will It Live Up to the Promise? One hundred years after the discovery of insulin, we are approaching a new frontier in diabetes management, says Dr Harpreet Bajaj.
  Medscape Diabetes & Endocrinology, September 24, 2020
  11
• Obesity and the Bitter Pill of Truth Obesity is encountered ubiquitously in clinical practice, with rates continuing to rise -- but why? Perhaps it's time we face the truth, says Dr Akshay Jain.
  Medscape Diabetes & Endocrinology, September 23, 2020
  207
• CGM in Type 2 Diabetes: Invaluable or Too Expensive? Is the value of using CGM in people with type 2 diabetes worth the cost? Dr Akshay Jain comments on a debate from ADA 2020.
  Medscape Diabetes & Endocrinology, July 21, 2020
  3
• VERTIS-CV Results 'Disappoint,' Raise More Questions The VERTIS-CV trial results presented at the ADA meeting raise more questions about the benefits of SGLT2 inhibitors than they answer, says Dr Harpreet Bajaj.
  Medscape Diabetes & Endocrinology, July 02, 2020
  3
• Is COVID-19 Fueling the Fire of Opinion-Based Medicine? This pandemic is causing people to turn to the 'pseudosciences' in their desperation to quickly save the world, writes Harpreet Bajaj.
  Medscape Diabetes & Endocrinology, June 04, 2020
  31
• The Links Between COVID-19 and Diabetes, Known and Unknown Dr Harpreet Bajaj summarizes the known and unknown links between diabetes and COVID-19, focusing on three clinical questions.
  Medscape Diabetes & Endocrinology, May 07, 2020
  2
• Cardios, Nephros, PCPs -- We're All Diabetologists Now Newer diabetes medications are proving effective in reducing CV events, hospitalizations for heart failure, and progression to dialysis. So where do these drugs belong?
  Medscape Diabetes & Endocrinology, March 05, 2020
  4
• Top 5 Diabetes Highlights From 2019 For the first time in several years, a cardiovascular outcomes trial may not be the most exciting diabetes news of the year. Here are 2019's highlights from Dr Harpreet Bajaj.
  Medscape Diabetes & Endocrinology, January 17, 2020
  2
• Recreational Marijuana in Diabetes: Not All Fun and Games   Dr Harpreet Bajaj discusses the potential harms of recreational cannabis use in people with type 1 and type 2 diabetes.
  Medscape Diabetes & Endocrinology, October 02, 2019
  4
• 'Poised on a Paradigm Shift': The REWIND and DECLARE Trials   Drs Harpreet Bajaj and Akshay Jain, coauthors of the Sugar Beat column, come together to discuss the results and clinical implications of the REWIND and DECLARE trials.
  Medscape Diabetes & Endocrinology, June 14, 2019
  4
• CREDENCE Takes SGLT2 Inhibitors 'to the Next Level' What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.
  Medscape Diabetes & Endocrinology, April 25, 2019
  7
• Fielding the Dangers of Fasting and Feasting With Diabetes Are you prepared to safely guide your Muslim patients with diabetes through Ramadan, their holy month of fasting? Here's what you need to know.
  Medscape Diabetes & Endocrinology, April 18, 2019
  31
• Diabetes 360: A Plan to Quell the 'Tsunami' of Diabetes Diabetes Canada's 360? framework can revolutionize diabetes prevention policies across the globe, says Harpreet Bajaj.
  Medscape Diabetes & Endocrinology, March 25, 2019
• Generic DPP-4 Inhibitors Would Be a 'Shot in the Arm' Dr Akshay Jain discusses the potential implications of a generic DPP-4 inhibitor for the management of type 2 diabetes that may soon enter the US market.
  Medscape Diabetes & Endocrinology, February 08, 2019
  8